How do you reduce off-target transgene expression in gene therapy?
De-targeting means selecting an element that is provably silent in the off-target tissue, with the same rigour as a positive hit. Here is how to measure a negative.
Do promoters selected in mice translate to primates and humans?
Regulatory-element function translates across species far less reliably than target biology. Around a quarter of mouse-active promoters kept targeting in primate; the lossy step is rodent-to-primate.
Does promoter activity in a plasmid predict AAV performance?
Episomal and integrated reporter assays rank regulatory elements differently. Matching assay topology to your vector, episomal for AAV, integrated for lentiviral, matters.
How do you increase a crop trait by editing regulatory DNA instead of knocking a gene out?
Many trait gains need upregulation or altered spatiotemporal expression, i.e. cis-regulatory change. As editing matures, the question is which edit to make, and that is answered by measuring expression, not predicting it.
Why does AAV transgene expression decline over time?
Late expression loss after AAV dosing is usually transcriptional silencing of a genome still present. The dominant mechanism is tissue-dependent, and the promoter is a design lever.
What is the trade-off between promoter strength and specificity?
Cell-type-restricted elements often sit below ubiquitous viral promoters on strength, but strong and specific elements do exist. The task is to find the best point on that frontier.
How do you design a cell-type-specific promoter for AAV gene therapy?
Annogen designs cell-type-restricted promoters by functionally measuring cis-regulatory activity across target and off-target cells with SuRE, not by inferring it from chromatin marks.
Heritable Agriculture, Annogen Agri collaborate on functional annotation to accelerate maize trait development
Agri Heritable Agriculture, Annogen Agri collaborate on functional annotation to accelerate maize trait development Amsterdam, The Netherlands & San Carlos, CA, U.S.A. Heritable Agriculture and Annogen Agri B.V. today announced a collaboration to functionally annotate non-coding variants in maize. Annogen will apply its SuRE™ platform to measure, directly in plant protoplasts, how these non-coding variants […]
Major acceleration of Annogen’s SuRE technology in seed and ag-biotech sector
Agri Major acceleration of Annogen’s SuRE technology in seed and ag-biotech sector 27 July 2026 Annogen is launcing its proprietary SuRE™ platform, which is used for functional annotation and improvement of promoters and enhancers, for applications in crop engineering. The powerful platform provides a massive-scale “blueprint” of a crop’s genetic regulatory landscape to pinpoint the specific […]
VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2
Advanced therapies VectorY’s VTx-002, featuring an Annogen promoter, cleared for ALS clinical trials phase 1&2 27 July 2026 Annogen is proud to announce a major milestone for our partner, VectorY Therapeutics, following the U.S. FDA’s IND clearance to proceed with the PIONEER-ALS Phase 1/2 Trial of VTx-002. This first-in-class vectorized antibody targets pathological TDP-43, the protein driving up […]
